Clinical Trial

A breakthrough BCI not only restores movement and sensation but promotes lasting change. Joyce Watson analyzes how Neuvotion is turning science into a business.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

Beam Therapeutics is set to unveil pivotal data for its AATD gene editor. Success could transform a disease and validate a multi-billion-dollar platform.

A new heart valve from Venus Medtech can be fully deployed and retrieved, giving surgeons an 'undo' button that could revolutionize patient safety.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

Spryte Medical's novel nOCT system offers microscopic views inside brain vessels. With its pivotal clinical trial enrollment complete, it's a step closer to FDA approval.

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.